Connectoma Neurotech

connectoma.com ↗ ·Madrid ·Seed

Connectoma Neurotech is a Madrid-based clinical neurotechnology company that develops personalised brain-stimulation treatment for mental health conditions. Its approach combines individual functional MRI brain mapping, AI analysis and neuronavigated transcranial magnetic stimulation (TMS). It targets treatment-resistant depression, anxiety associated with depression, OCD and substance-use disorders. Founded in 2024, it works B2B and B2B2C through partner clinics such as Veram in Madrid and HT Médica in Seville, alongside academic partners including Universidad Complutense and ANT Neuro. It raised a €1.25 million initial round, backed by Bolboreta Innova Group and strategic investors from mental health, among them psychiatrist Marian Rojas Estapé.

Founded

2024

Founders

Total funds raised

€1.2M

SectorsHealthtech, Neurotechnology, Mental health, Medical devices, Artificial intelligence Start-up MapHealthtech & Bio › Medical devices & surgical hardware

Suggest a correction

Founders

Alfonso Tames Llana

Co-founder & CTO

Daniel Díez

Co-founder & CEO

Jaime Adán Manes

Co-founder & CSO

Global models 5

Neuronetics

United States · neurostar.com ↗

Sells its NeuroStar TMS system for treatment-resistant depression to psychiatry practices and clinics, which then treat the patients. That is the same B2B/B2B2C clinic-partner route Connectoma uses for TMS-based mental-health treatment (figure is private equity raised before its 2018 IPO).

$187MComparable

Magnus Medical

United States · magnusmed.com ↗

Closest match: its SAINT system uses each patient's own functional MRI connectivity map to choose a personalised, neuronavigated TMS target for treatment-resistant depression, and health systems and clinics deliver it.

$89MComparable

Nexstim

Finland · www.nexstim.com ↗

Builds MRI-based, neuronavigated TMS systems, including a navigated depression therapy, and sells them to hospitals and clinics. That is the same image-guided, personalised-targeting approach Connectoma takes (figure is the more than €30M private equity raised before its listing, converted roughly).

$40MComparable

Greenbrook TMS

Canada · www.greenbrooktms.com ↗

Runs a network of outpatient TMS treatment centres for treatment-resistant depression and OCD, which is the clinic-delivered TMS service side of Connectoma's model. I found no sourced figure for its private equity before the IPO.

raised —Comparable

Mindful Health Solutions

United States · mindfulhealthsolutions.com ↗

A venture-backed US clinic network (Norwest, WP Global Partners) offering TMS and esketamine for treatment-resistant depression, mirroring Connectoma's clinic-based treatment model. Its total equity raised is not disclosed.

raised —Comparable

In the same niche 72 others

See all in the Start-ups Map →

Anaconda Biomed

Sant Cugat del Vallès

Series C · €90.1M

INBRAIN Neuroelectronics

Venture Debt · €71.2M

Medlumics

Madrid

No stage disclosed · €57.8M

+66 more →

Notes: Most funded first

Investors 2

Open as list →

Bolboreta Innova Group

www.bolboretainnova.com

Investor Spain

Marian Rojas Estapé

marianrojas.com ↗

Seed 2026 HQ unknown

Funding rounds 1

Date	Round	Amount	Lead
2026-04-27	Seed (estimated)	€1.25M	Lead not disclosed +1 more

News 2

Open as list →

Published	Article
2026-06-29	HT Médica y Connectoma incorporan resonancia magnética funcional avanzada para personalizar tratamientos de depresión resistente ↗ HT Médica (press release) 2026-06-29
2026-04-27	Connectoma arrives in Madrid: up to 79% remission for resistant depression in 5 days ↗ Demócrata +1 source 2 reportsfirst 2026-04-27 Connectoma arrives in Madrid: up to 79% remission for resistant depression in 5 daysDemócrata · 2026-04-27↗ Connectoma llega a Madrid: hasta 79% de remisión para depresión resistente en 5 díasDemocrata.es · 2026-04-27↗ 2026-04-27